1. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly
- Author
-
Mariano Galdiero, Annamaria Colao, Gaetano Lombardi, Diego Ferone, Alberto Rebora, Francesco Minuto, Renata S. Auriemma, Eugenia Resmini, Rosario Pivonello, Colao, Annamaria, Auriemma, R. S., Rebora, A., Galdiero, M., Resmini, E., Minuto, F., Lombardi, Gaetano, Pivonello, Rosario, and Ferone, D.
- Subjects
Adenoma ,Adult ,Male ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,First line ,Antineoplastic Agents ,Lanreotide ,Peptides, Cyclic ,Acromegalia ,chemistry.chemical_compound ,Endocrinology ,Internal medicine ,Acromegaly ,Medicine ,Humans ,Prospective Studies ,Insulin-Like Growth Factor I ,Adverse effect ,Shrinkage ,Aged ,Dose-Response Relationship, Drug ,business.industry ,Human Growth Hormone ,Lanreotide Autogel ,Middle Aged ,medicine.disease ,GH ,IGF-I ,Tumor Burden ,Safety profile ,Treatment Outcome ,chemistry ,Female ,business ,Somatostatin ,After treatment - Abstract
To evaluate GH and IGF-I control and tumour shrinkage in newly diagnosed patients with acromegaly treated first-line with lanreotide-Autogel (ATG) 120 mg. Design Open, prospective.Twenty-six patients (17 women, aged 31-70 years): eight enclosed and 12 extrasellar (eight invasive) macroadenomas and six microadenomas (one invasive). ATG 120 mg initially given every 4 weeks for 12 weeks; then intervals between injections increased to every 6 or 8 weeks if GH levels wereor= 2.5 or1 microg/l (equal to 6.5 and 2.6 mU/l), respectively.Final dosage was ATG 120 mg every 4 weeks in nine patients (34.6%), every 6 weeks in eight patients (30.8%) and every 8 weeks in the remaining nine patients (34.6%). After 12 months, both GH and IGF-I were controlled in 14 patients (53.8%). The mean tumour volume decreased from 1405 +/- 1827 mm(3) at study entry to 960 +/- 1381 mm(3) after 6 months, and 799 +/- 1161 mm(3) after 12 months (P0.0001). Overall tumour shrinkage was 35.8 +/- 28.1% after 6 months and 48.4 +/- 27.6% after 12 months. After 12 months, 20 patients (76.9%) achieved25% tumour shrinkage: 12 of 14 with controlled disease (85.7%) and 8 of 12 with noncontrolled disease (66.7%; P = 0.49). Hyperhydrosis, paresthesiae and arthralgias significantly reduced after treatment. No patient withdrew from the study because of adverse events.ATG 120 mg in newly diagnosed patients with acromegaly controls GH and IGF-I secretion in 53.8% and inducesor= 25% tumour shrinkage in 76.9% during a 12-month period. The treatment was associated with improvement of clinical symptoms and with a good safety profile.
- Published
- 2008